Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 8:00 a.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 8:00 a.m. E.T. The event will feature key members of the senior leadership team discussing the company's initiatives.
A live audio webcast of the presentation can be accessed via Amicus Therapeutics' investor section on their corporate website.
Amicus is dedicated to developing high-quality medicines for rare metabolic diseases, emphasizing innovation and patient care.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was +1.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T.
A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
CONTACT:
Investors:
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.